FY28 revenue target of $400 million
Reaffirmed organic revenue guidance of $400 million for FY28, driven by semaglutide DDC and base business growth.
ONESOURCESPECIALTYPHARMA / guidance tracker
Keep management guidance in view.
Onesource Specialty Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY28 EBITDA margin target of ~40%
Reaffirmed EBITDA margin guidance of approximately 40% for FY28, supported by operating leverage from capacity expansion.
Second DDC line commercial in Q2 FY27
The second drug-device combination line is undergoing qualification and will be available for commercial manufacturing from Q2 FY27.
Third DDC line by end of FY27
A third DDC line will be installed and operational by the end of FY27, bringing total lines to three.